A new naloxone nasal spray will soon be available.
A new naloxone nasal spray will soon be available.
RiVive will soon be available without a prescription for the treatment of known or suspected opioid overdose.
Patients will no longer need a prescription for this opioid overdose antidote.
A new 8 mg naloxone nasal spray will soon be available, which is the largest naloxone dose approved by the FDA to date.
The FDA recommends healthcare professionals co-prescribe the opioid overdose reversal drug with all opioid prescriptions.
The life saving antidote for opioid overdose will soon be available in a consumer-friendly, generic nasal spray.
Four research sites will test proven opioid prevention and treatment interventions, hoping to reduce overdose deaths by 40% over three years.
The FDA created special drug labels to clear a development hurdle and encourage manufacturers.
